Anti-Human PD-L1 Reference Antibody (Lesabelimab, RUO) (HV974206)

Name: Anti-Human PD-L1 Reference Antibody (Lesabelimab, RUO)
Brand: abinScience
SKU: HV974206
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号

HV974206

説明

Lesabelimab (HV974206) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

種反応性

Human

アプリケーション

ELISA, Bioactivity: FCM, Functional assay, Research in vivo, WB

宿主種

Human

クローン性

Monoclonal

アイソタイプ

IgG1-kappa

テスト済みアプリケーション

ターゲット

B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

エンドトキシンレベル

< 10 EU/mg

純度

>95% as determined by SDS-PAGE.

精製

Protein A/G purified from cell culture supernatant.

アクセッション番号

Q9NZQ7

形態

Liquid

保存バッファー

0.01M PBS pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

製品使用情報

アプリケーション	希釈
WB	1:500-1:2000

安定性と保存

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

別名

LDP, 2475402-56-1

背景

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

注意事項

For research use only. Not suitable for clinical or therapeutic use.

イメージ

SDS-PAGE

SDS-PAGE for Research Grade Lesabelimab.
Bioactivity

Detects recombinant PDL1 (Catalog No: HV974011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-PDL1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human PDL1 (Catalog No: HV974011)
Lane 2: Negative control